Nutriband Inc. — Form 10-Q Summary
Reporting period: Three months ended April 30, 2023, compared with the three months ended April 30, 2022. The company’s fiscal year ends January 31, making this its fiscal first quarter of 2024. Financial statements are unaudited; amounts below are in U.S. dollars.
Business context
Nutriband develops transdermal pharmaceutical products, led by its AVERSA abuse-deterrent fentanyl patch, which requires further development and FDA approval. Current revenue comes mainly from coated and transdermal product manufacturing through Pocono Pharmaceuticals, plus research and development services through 4P Therapeutics. The company reported no revenue from products under development.
Key financial results
| Metric | Q ended Apr. 30, 2023 | Q ended Apr. 30, 2022 |
|---|---|---|
| Revenue | $476,932 | $477,922 |
| Gross profit | $222,284 | $200,486 |
| Gross margin | 46.6% | 42.0% |
| Operating loss | $(1,017,878) | $(685,879) |
| Net loss | $(1,015,229) | $(689,989) |
| Net loss per share, basic and diluted | $(0.13) | $(0.08) |
| Cash used in operating activities | $(749,864) | $(744,257) |
Revenue was nearly unchanged. Cost of revenue declined, lifting gross profit, but higher research and development and selling, general and administrative expenses widened the operating and net losses. R&D expense was $400,430, compared with $117,814 in the statements (the MD&A cites $117,184 for the prior period). SG&A was $839,732 versus $768,551; the company attributed much of the increase to approximately $162,000 in noncash equity compensation. The filing reports $5,815 of interest income and $3,166 of interest expense in the current quarter.
Liquidity, cash flow and debt
- At April 30, 2023, cash and cash equivalents were $1,278,075, down from $1,985,440 at January 31, 2023. Working capital was $1,209,099, compared with $1,945,132.
- Quarterly cash flows included $2,624 used in investing activities and $45,123 provided by financing activities. Financing included a $50,000 draw on a related-party credit facility, partly offset by $4,877 of note principal payments.
- Total liabilities were $955,821, including $19,931 of current notes payable, $95,429 of long-term notes payable and a $50,000 related-party note. The company also had operating lease liabilities.
- In March 2023, Nutriband entered a three-year, $2 million credit-line agreement with TII Jet Services LDA, a shareholder-owned entity. Advances bear 7% interest and mature March 19, 2026; only $50,000 had been drawn by quarter-end.
Changes, outlook and risks
- Management estimates approximately $13 million will be needed to develop the lead fentanyl product, including clinical manufacturing and trials; the filing notes total costs could be higher. A feasibility workplan with Kindeva was estimated at approximately $2.1 million, with an expected duration of 8–15 months. The company recorded $400,430 of related R&D expense in the quarter.
- Management said it expects available resources and forecast operations to fund the business for at least one year from issuance and believes substantial doubt about going concern is alleviated. This assessment is alongside a quarterly operating loss, operating cash use, a history of losses and reliance on external financing.
- Material risks include the need for additional capital, uncertain clinical and FDA outcomes, possible development delays and the absence of a product the company can market in the United States. The filing also identifies potential pandemic-related disruptions to operations, suppliers and clinical timelines.
- Disclosure controls and procedures were reported ineffective. Management cited material weaknesses involving segregation of duties and qualified accounting staffing, while describing added accounting personnel and monitoring controls. No material control changes during the quarter were reported.
- Other notable items: $162,120 of warrants and options were issued for services; a new executive option grant was valued at $75,030. The company reported no legal proceedings and no material subsequent events requiring adjustment.
Most important facts for investors to verify
- Whether the cash balance, quarterly cash burn and undrawn portion of the related-party credit line are sufficient to fund the AVERSA development plan and operating needs.
- The actual development, clinical-trial and FDA-approval timeline and total funding required, including whether additional financing will be necessary.
- The filing’s period presentation: the index refers to cash flows for “nine months,” while the cash-flow statement and comparative results presented cover three months.
- The prior-period R&D amount differs within the filing: $117,814 in the income statement and segment table versus $117,184 in MD&A.
- Potential dilution and governance implications of outstanding warrants/options and the shareholder-affiliated credit facility; the filing reports 1,783,373 common-stock equivalents excluded from diluted EPS as anti-dilutive.